stockportfolio.pro
Stocks / DFTX vs GRAL
DFTX vs GRAL
Definium Therapeutics, Inc. and GRAIL, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Definium Therapeutics, Inc. (DFTX) | GRAIL, Inc. (GRAL) | |
|---|---|---|
| Market cap | $2.6B | $2.6B |
| Revenue (latest FY) | $0 | $147.17M |
| Net income (latest FY) | $-183.79M | $-408.35M |
| Revenue growth (5y CAGR) | — | 38.4% |
| Net margin | — | -277.5% |
| Return on equity | -55.3% | -15.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DFTX — free Open GRAL — freeFrequently asked questions
Which is bigger, DFTX or GRAL?
GRAIL, Inc. is larger by market capitalization — $2.6B versus $2.6B.
Which grows faster, DFTX or GRAL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.